In the news

A presentation from WIRED Health 2024 discusses how Boston Scientific is advancing technologies to transform chronic pain care today and in the future.

The first coronary drug-coated balloon to be FDA-approved in the U.S., the Boston Scientific AGENT^TM Drug-Coated Balloon addresses a clinical unmet need by treating and preventing reoccurrence of in-stent restenosis in patients with coronary artery disease.

Boston Scientific shares how real-world data can help optimize physician decision making when treating patients with pulmonary embolism (PE).

Lisa Considine, vice president of human resources, and Adriana Gonzalez, director of global supply chain, share how Boston Scientific’s on-site day care in Marlborough, MA provides support and flexibility for employees while reinforcing an organizational culture of caring.

Next generation spinal cord stimulation devices, including Boston Scientific’s WaveWriter Alpha^TM SCS System, are providing relief to people living with diabetic peripheral neuropathy who are unresponsive to drugs or experience side effects.